Navigation Links
Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same
Date:5/25/2013

Oakland, CA (PRWEB) May 25, 2013

Dennis R. HIll M.D. Radiation Oncologist at the Alta Bates Summit Medical Center in Oakland, CA reports that recently there has been a promotion of the idea that a newer isotope Cesium 131 has markedly improved the permanent seed, or low dose rate, brachytherapy for prostate cancer. The claim is that this newer isotope has a higher energy, a shorter half life, and gives a higher biologically effective dose to the tumor. It is true that Cesium 131 has a higher average energy than the other commonly used prostate cancer permanent seed isotopes on the market. The more commonly used isotopes used are Palladium 103 and Iodine 125. Cesium 131 delivers 90% of the prescribed dose to the prostate gland in 33 days compared to 58 days for Palladium 103 and 204 days for Iodine 125. Another claimed benefit to the short half-life of Cesium 131 is what is known as the “biological effective dose” against cancers exhibiting different characteristics – for instance, slow versus fast growing tumors. This all sounds good and it is an improvement over conventional low dose rate permanent seed brachytherapy with Palladium 103 or Iodine 125.

Dr. Hill answers the question, how does Cesium 131 compares to temporary high dose rate brachytherapy, one of the newest prostate cancer treatment options? High dose rate brachytherapy delivers the entire dose in two treatments over eight days compared to 33 days with Cesium 131. Prostate cancer, unlike some other cancers can have a slower growth rate which can be closer to normal tissue than the more virulent cancers. Research has shown that larger doses of radiation over a shorter period of time as delivered by high dose rate brachytherapy may be radiobiologically superior to the protracted low doses over a long time that permanent seeds delivers, including Cesium 131. Since high dose rate brachytherapy for prostate cancer is a temporary implant there is no radioactive source left in the patient. Cesium 131 is still a permanent seed implant with the same limitations compared to high dose rate brachytherapy. The Cesium 131 seeds are all of uniform strength so it is very difficult to get uniformity of dose with proper spacing of the seeds. The seeds are implanted into deformable tissue and once the seed is implanted it can’t be moved. The dose plan is still done as an estimated pre-plan prior to surgery or on the fly with “real time intra-operative planning” at the time of surgery. In either case the doses are calculated AFTER the implant. In contrast, with high dose rate brachytherapy the implant catheters and treatment positions are known and the dose can be designed in advance of the source delivery. The final treatment plan is completed and approved by the physician before rather than during or after the source is administered.

Dr. Hill notes that other disadvantages of a permanent seed implant are unchanged by the type of isotope. There can be anatomic changes or migration of seeds during the time it takes the permanent seeds to emit the dose, the permanent seeds cannot be placed at the capsule because there is no anchoring tissue, there are prostate size limitations, the bony pubic arch may limit the implant, and so on.

Although Cesium 131 appears to have an advantage over other permanent seed isotopes, in Dr. Hill’s opinion the overall advantage still goes to temporary interstitial high dose rate brachytherapy.

About Dennis R. Hill MD

Dr. Hill has been doing High Dose Rate Brachytherapy exclusively since 2004. He has done over five hundred High Dose Rate Prostate Brachytherapy implants and has published scholarly articles on the subject. His office is located at: Dennis R. Hill MD 3012 Summit Street Suite 2675 Oakland, CA 94609 510-869-8875 drh(at)dennisrhillmd(dot)com and his website is hdrprostatebrachytherapy.com, which includes a quiz to determine if a patient is a candidate for HDR Prostate Brachytherapy.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10768506.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors
2. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
3. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
4. Urologists Debunk Misleading, Grossly Inaccurate Prostate Cancer Biopsy Study
5. Urologists Outraged over Government Panels Recommendation to Stop Life-Saving Prostate Cancer Testing
6. Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
7. Gold nanoparticles could treat prostate cancer with fewer side effects than chemotherapy
8. Safeway Raises Over $9 Million to Fund Prostate Cancer Research
9. Genomic Health Announces Positive Topline Results of Large Prostate Cancer Clinical Validation Study; Company to Proceed with 2013 Commercial Launch
10. Prostate Cancer Medical Websites: Friend Or Foe?
11. University of College London Hospitals (UCLH) Selects GEO SCAN Medical as New Standard of Care for the Detection and Treatment of Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... SAN FRANCISCO , June 22, 2016  Amgen ... platinum sponsorship of the QB3@953 life sciences ... improve human health. The shared laboratory space at QB3@953 ... startups overcome a key obstacle for many early stage ... As part of the sponsorship, Amgen launched two "Amgen ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):